Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aviv Philip Goncharov has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Bohuslav Melichar

    Department of Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic

    1 shared publication
  • Constantinos Dicusari Elissaiou

    Department of Clinical and Molecular Pathology, Palacky University

    1 shared publication
  • Daniela Skanderova

    Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic

    1 shared publication
  • Elad Ben Aharon Farzalla

    Department of Clinical and Molecular Pathology, Palacky University

    1 shared publication
  • Giorgi Akhvlediani

    Faculty of Medicine, Georgian-American University

    1 shared publication
  • Gvantsa Kharaishvili

    Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacký University Olomouc, Olomouc, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    A case report of perioperative immune checkpoint inhibitor therapy achieving long-term disease control in TFEB-amplified renal cell carcinoma

    by Martina Spisarova, Aviv Philip Goncharov, Gvantsa Kharaishvili, Daniela Skanderova, Jakub Olejko, Katerina Hola, Vladimir Student, Igor Hartmann, Hana Studentova, Bohuslav Melichar

  • Open Access

    Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer

    by Aviv Philip Goncharov, Constantinos Dicusari Elissaiou, Elad Ben Aharon Farzalla, Giorgi Akhvlediani, Nino Vashakidze, Gvantsa Kharaishvili

    From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.


  • Open Access

    Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies

    by Aviv Philip Goncharov, Nino Vashakidze, Gvantsa Kharaishvili

    Epithelial-mesenchymal transition (EMT) is a crucial and fundamental mechanism in many cellular processes, beginning with embryogenesis via tissue remodulation and wound healing, and plays a vital role in tumorigenesis and metastasis formation. EMT is a complex process that involves many transcription factors and genes that enable the tumor cell to leave the primary location, invade the basement membrane, and send metastasis to other tissues. Moreover, it may help the tumor avoid the immune system and establish radioresistance and chemoresistance. It may also change the normal microenvironment, thus promoting other key factors for tumor survival, such as hypoxia-induced factor-1 (HIF-1) and promoting neoangiogenesis. In this review, we will focus mainly on the role of EMT in benign prostate disease and especially in the process of establishment of malignant prostate tumors, their invasiveness, and aggressive behavior. We will discuss relevant study methods for EMT evaluation and possible clinical implications. We will also introduce clinical trials conducted according to CONSORT 2010 that try to harness EMT properties in the form of circulating tumor cells to predict aggressive patterns of prostate cancer. This review will provide the most up-to-date information to establish a keen understanding of the cellular and microenvironmental processes for developing novel treatment lines by modifying or blocking the pathways.